Home  »  News   »  Intra-Cellular Therapies Inc. (ITCI): Are the Star...

Intra-Cellular Therapies Inc. (ITCI): Are the Stars Lining Up for Investors?

At the end of the latest market close, Intra-Cellular Therapies Inc. (ITCI) was valued at $55.23. In that particular session, Stock kicked-off at the price of $56.02 while reaching the peak value of $58.97 and lowest value recorded on the day was $54.8351. The stock current value is $58.31.Recently in News on June 13, 2022, Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience. Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience held virtually June 10-12, 2022. You can read further details here

Intra-Cellular Therapies Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $66.00 on 04/07/22, with the lowest value was $38.51 for the same time period, recorded on 01/21/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Intra-Cellular Therapies Inc. (ITCI) full year performance was 46.69%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intra-Cellular Therapies Inc. shares are logging -11.65% during the 52-week period from high price, and 105.32% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $28.40 and $66.00.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 628090 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Intra-Cellular Therapies Inc. (ITCI) recorded performance in the market was 11.41%, having the revenues showcasing -6.09% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 5.66B, as it employees total of 512 workers.

Market experts do have their say about Intra-Cellular Therapies Inc. (ITCI)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 56.62, with a change in the price was noted +12.01. In a similar fashion, Intra-Cellular Therapies Inc. posted a movement of +25.94% for the period of last 100 days, recording 916,018 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ITCI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of Intra-Cellular Therapies Inc. (ITCI)

Raw Stochastic average of Intra-Cellular Therapies Inc. in the period of last 50 days is set at 78.26%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 80.97%. In the last 20 days, the company’s Stochastic %K was 67.87% and its Stochastic %D was recorded 63.59%.

Bearing in mind the latest performance of Intra-Cellular Therapies Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 11.41%. Additionally, trading for the stock in the period of the last six months notably improved by 11.15%, alongside a boost of 46.69% for the period of the last 12 months. The shares increased approximately by 7.44% in the 7-day charts and went up by 0.05% in the period of the last 30 days. Common stock shares were lifted by -6.09% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts